Quarterly report [Sections 13 or 15(d)]

Consolidated Financial Statements Details

v3.25.1
Consolidated Financial Statements Details
3 Months Ended
Mar. 31, 2025
Condensed Consolidated Financial Statement Details  
Consolidated Financial Statement Details

3. Condensed Consolidated Financial Statements Details

Equity Securities

As of March 31, 2025 and December 31, 2024, investment in equity securities was $2.4 million and $3.5 million, respectively. For the three months ended March 31, 2025 and 2024, the Company recognized a loss of $1.1 million and a gain of $0.3 million, respectively, due to the change in fair value of its investment in equity securities in the other income (expense), net line item of the condensed consolidated statements of operations.

Intangible Assets, Net

The following table summarizes the cost, accumulated amortization, and net carrying value of the Company’s intangible assets as of March 31, 2025 (in thousands):

Accumulated

Net Carrying

Cost

Amortization

Value

As of March 31, 2025

Pulmokine - Seralutinib IP (Note 4)

$

26,115

$

750

$

25,365

Total intangible assets

$

26,115

$

750

$

25,365

The following table summarizes the cost, accumulated amortization, impairment charge, and net carrying value of the Company’s intangible assets as of December 31, 2024 (in thousands):

Accumulated

Net Carrying

Cost

Amortization

Value

As of December 31, 2024

Pulmokine - Seralutinib IP (Note 4)

$

26,115

$

206

$

25,909

Total intangible assets

$

26,115

$

206

$

25,909

The estimated remaining life of the intangible assets is 11.7 years. The following table presents the projected amortization expense for the next five years (in thousands):

Intangible Asset

    

Amortization

2025 (excluding the three months ended March 31, 2025)

$

1,632

2026

 

2,176

2027

2,176

2028

2,176

2029

2,176

Total

$

10,336

Net Income (Loss) Per Share Available to (Attributable to) Common Stockholders

The following table includes the computation of basic and diluted net income (loss) per share available to (attributable to) common stockholders (in thousands, except per share amounts):

Three Months Ended March 31, 

2025

2024

Numerator

Net income (loss)

$

2,367

$

(8,595)

Less: Series A accumulated dividends

 

(530)

 

(530)

Less: Series B accumulated dividends

(838)

(838)

Less: Allocation of undistributed earnings to participating securities

(294)

Net income (loss) available to (attributable to) common stockholders, basic

$

705

$

(9,963)

Add: Adjustments to undistributed earnings allocated to participating securities

 

294

Net income (loss) available to (attributable to) common stockholders, diluted

$

999

$

(9,963)

 

Denominator

 

 

Weighted-average shares used in computing net income (loss) per share available to (attributable to) common stockholders, basic

 

11,969

 

11,580

Effect of dilutive Series X Preferred Stock

5,003

Effect of dilutive warrants for common stock

2

Effect of dilutive PSUs

 

273

Effect of dilutive common stock options

 

534

Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted

 

17,781

 

11,580

Net income (loss) per share available to (attributable to) common stockholders, basic

$

0.06

$

(0.86)

Net income (loss) per share available to (attributable to) common stockholders, diluted

$

0.06

$

(0.86)

Potentially dilutive securities are excluded from the calculation of diluted net income (loss) per share available to (attributable to) common stockholders if their inclusion is anti-dilutive.

The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income (loss) per share available to (attributable to) common stockholders (in thousands):

Three Months Ended March 31, 

2025

2024

Convertible preferred stock

5,003

Common stock options

 

1,094

1,372

Contingently issuable PSUs

Warrants for common stock

 

120

131

Total

 

1,214

 

6,506

For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. For market conditions that have not yet been satisfied, no shares would be issuable based on the market price of $19.93 per share as of March 31, 2025.

For PSUs that have satisfied the market conditions but have not satisfied service conditions by the end of the reporting period, the number of shares issuable is included in the calculation of diluted earnings per share if the effect is dilutive. This includes PSUs that achieved the $30.00 price target in November 2024, but still have remaining time-based vesting requirements.

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

March 31, 

December 31, 

    

2025

    

2024

Accrued short-term interest payable

$

$

3,039

Accrued incentive compensation

434

1,555

Accrued clinical liabilities

26

306

Income taxes payable in connection with Pulmokine acquisition

280

Accrued legal and accounting fees

482

251

Accrued payroll and benefits

149

170

Other accrued liabilities

 

130

 

151

Total

$

1,221

$

5,752